Compare HTCR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | JAGX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.9M |
| IPO Year | 2022 | 2014 |
| Metric | HTCR | JAGX |
|---|---|---|
| Price | $2.65 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 27.8K | ★ 160.3K |
| Earning Date | 05-14-2026 | 04-07-2026 |
| Dividend Yield | ★ 87.84% | N/A |
| EPS Growth | ★ 414.29 | 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,407,229.00 | $11,511,000.00 |
| Revenue This Year | $123.26 | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.22 |
| 52 Week High | $3.97 | $8.00 |
| Indicator | HTCR | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 33.57 |
| Support Level | $2.43 | $0.60 |
| Resistance Level | $2.91 | $1.04 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 62.05 | 38.71 |
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.